Free Trial

Enovis (ENOV) Competitors

Enovis logo
$39.39 -0.61 (-1.53%)
As of 03:58 PM Eastern

ENOV vs. STVN, GKOS, BLCO, INSP, NARI, IRTC, PRCT, NVST, TMDX, and SLNO

Should you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), Envista (NVST), TransMedics Group (TMDX), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry.

Enovis vs.

Enovis (NYSE:ENOV) and Stevanato Group (NYSE:STVN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends.

Enovis has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Enovis and Stevanato Group both received 30 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
EnovisOutperform Votes
30
62.50%
Underperform Votes
18
37.50%
Stevanato GroupOutperform Votes
30
62.50%
Underperform Votes
18
37.50%

98.4% of Enovis shares are owned by institutional investors. 2.4% of Enovis shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Enovis currently has a consensus target price of $58.50, suggesting a potential upside of 48.51%. Given Enovis' stronger consensus rating and higher possible upside, research analysts clearly believe Enovis is more favorable than Stevanato Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enovis
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Stevanato Group
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

Stevanato Group has a net margin of 10.47% compared to Enovis' net margin of -5.95%. Stevanato Group's return on equity of 9.86% beat Enovis' return on equity.

Company Net Margins Return on Equity Return on Assets
Enovis-5.95% 4.39% 2.80%
Stevanato Group 10.47%9.86%5.79%

Stevanato Group has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enovis$2.11B1.06-$33.26M-$14.29-2.76
Stevanato Group$1.10B5.83$157.62M$0.4844.29

In the previous week, Stevanato Group had 3 more articles in the media than Enovis. MarketBeat recorded 8 mentions for Stevanato Group and 5 mentions for Enovis. Enovis' average media sentiment score of 1.43 beat Stevanato Group's score of 1.21 indicating that Enovis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enovis
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Stevanato Group
7 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Stevanato Group beats Enovis on 9 of the 16 factors compared between the two stocks.

Remove Ads
Get Enovis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENOV vs. The Competition

MetricEnovisSurgical appliances & supplies IndustryMedical SectorNYSE Exchange
Market Cap$2.24B$9.14B$5.68B$19.75B
Dividend YieldN/A1.41%4.55%3.75%
P/E Ratio-17.9917.6824.5534.05
Price / Sales1.0670.05395.7228.57
Price / Cash6.8619.6738.1617.54
Price / Book0.635.657.064.63
Net Income-$33.26M$284.66M$3.19B$1.02B
7 Day Performance1.03%2.33%1.49%1.12%
1 Month Performance-6.40%-1.93%5.87%-1.07%
1 Year Performance-34.65%-15.84%14.94%7.08%

Enovis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENOV
Enovis
2.8272 of 5 stars
$39.39
-1.5%
$58.50
+48.5%
-33.5%$2.24B$2.11B-17.996,550Positive News
STVN
Stevanato Group
1.6585 of 5 stars
€20.71
+3.4%
N/A-28.0%$6.27B$1.10B44.065,635Positive News
GKOS
Glaukos
4.5395 of 5 stars
$103.12
+0.9%
$163.25
+58.3%
+22.3%$5.83B$383.48M-35.93780Positive News
BLCO
Bausch + Lomb
3.7682 of 5 stars
$15.39
+0.3%
$20.00
+29.9%
-1.6%$5.43B$4.79B-16.9212,500News Coverage
INSP
Inspire Medical Systems
4.7036 of 5 stars
$166.59
+2.7%
$228.82
+37.4%
-13.4%$4.94B$802.80M96.291,246Positive News
NARI
Inari Medical
0.936 of 5 stars
$79.97
flat
$68.00
-15.0%
N/A$4.68B$493.63M-59.24800
IRTC
iRhythm Technologies
1.5315 of 5 stars
$103.70
+3.0%
$119.73
+15.5%
-2.3%$3.26B$591.84M-28.491,790Positive News
Gap Up
PRCT
PROCEPT BioRobotics
3.0601 of 5 stars
$59.03
+2.4%
$94.29
+59.7%
+27.8%$3.24B$224.50M-30.27430News Coverage
NVST
Envista
4.1292 of 5 stars
$17.16
+3.0%
$20.18
+17.6%
-17.9%$2.95B$2.51B-2.6412,700
TMDX
TransMedics Group
3.051 of 5 stars
$67.69
-1.2%
$122.70
+81.3%
+0.9%$2.28B$441.54M72.01210
SLNO
Soleno Therapeutics
4.4317 of 5 stars
$49.63
+0.6%
$71.20
+43.5%
+19.4%$2.28BN/A-14.9530
Remove Ads

Related Companies and Tools


This page (NYSE:ENOV) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners